Are you worried your memory or performance is not as sharp as it used to be? Not all memory problems are a sign of dementia. And even in those who do develop dementia, Alzheimer’s disease accounts for only about 50% of cases. Treatable vascular disease accounts for up to 40% of older adults with memory impairment. Many of the remaining cases turn out to be related to other identifiable underlying causes that can be corrected. PLC’s Memory & Cognitive Health Program detects the treatable problems that lead to memory loss and reduced cognitive function and identify reduced function that comes with normal aging.
The Memory & Cognitive Health Program assesses the many conditions that can affect memory and cognitive health including stress, fatigue, sleep disturbances as well as screen for signs of Alzheimer’s and dementia. The Structural Brain MRI adds Quantitative Brain MRI Imaging to your Memory & Cognitive Health Program to look for evidence of loss of nerve cells in the areas related to memory. This is also an advanced tool that can rule out (or in) problems that affect memory and cognitive function like small or large strokes, fluid buildup around the brain, brain tumors, brain trauma or atrophy as well as measure brain volume. For patients identified with true cognitive impairment, advanced PET/CT Amyloid Imaging is available to provide early detection of the accumulation of abnormal proteins in the brain that are indicative of developing Alzheimer’s disease.
Get an objective assessment of your current cognitive status including memory, problem solving, executive function, language, processing speed and more. Differentiate “normal aging” from impairments that may be symptomatic of more severe underlying issues years before illness becomes apparent. Create a baseline to track your memory and cognitive function over time.
At-Home Screening for sleep apnea and sleep disturbances that can affect your memory and cognitive function.
Screen for prior strokes, brain tumors, atrophy of brain tissue and other causes of memory changes. Quantitative Brain MRI analysis allows early detection of loss of neurons in the areas of the brain that control memory functions.
Provides early detection of accumulation of abnormal proteins in the brain that are the earliest indicators of developing Alzheimer’s Disease.
Testing for APP and Presenilin Mutations associated with early-onset Alzheimer Disease. Recommended for symptomatic patients with early-onset Alzheimer Disease and family history of dementia or those with a family history of one or more cases of early-onset Alzheimer Disease